$0.75 EPS Expected for iTeos Therapeutics, Inc. (NASDAQ:ITOS) This Quarter

Equities research analysts expect iTeos Therapeutics, Inc. (NASDAQ:ITOS) to post $0.75 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for iTeos Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.82) and the highest estimate coming in at $1.48. iTeos Therapeutics reported earnings per share of ($0.43) during the same quarter last year, which would suggest a positive year over year growth rate of 274.4%. The business is scheduled to announce its next earnings report on Wednesday, March 23rd.

According to Zacks, analysts expect that iTeos Therapeutics will report full year earnings of $4.64 per share for the current year, with EPS estimates ranging from $1.53 to $10.20. For the next year, analysts anticipate that the company will report earnings of $1.90 per share, with EPS estimates ranging from ($4.96) to $5.07. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow iTeos Therapeutics.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Wednesday, November 10th. The company reported $1.86 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $4.95 by ($3.09). During the same quarter in the previous year, the firm earned ($0.48) EPS.

Several equities analysts recently weighed in on the stock. SVB Leerink cut their price target on shares of iTeos Therapeutics from $55.00 to $54.00 and set an “outperform” rating on the stock in a report on Friday, November 12th. Piper Sandler cut their price target on shares of iTeos Therapeutics from $50.00 to $42.00 and set an “overweight” rating on the stock in a report on Thursday, November 11th. Finally, Zacks Investment Research downgraded shares of iTeos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $43.80.

NASDAQ:ITOS traded up $0.56 during midday trading on Thursday, hitting $36.98. The company’s stock had a trading volume of 276,981 shares, compared to its average volume of 301,232. iTeos Therapeutics has a fifty-two week low of $17.43 and a fifty-two week high of $47.61. The company’s 50 day simple moving average is $29.02. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of 127.52 and a beta of 1.94.

In other iTeos Therapeutics news, CEO Michel Detheux sold 14,500 shares of the firm’s stock in a transaction on Tuesday, November 23rd. The stock was sold at an average price of $36.08, for a total value of $523,160.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 1,149 shares of the firm’s stock in a transaction on Thursday, October 7th. The shares were sold at an average price of $27.00, for a total value of $31,023.00. The disclosure for this sale can be found here. Insiders have sold a total of 532,153 shares of company stock worth $16,048,904 in the last ninety days. Corporate insiders own 3.95% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. EcoR1 Capital LLC raised its holdings in shares of iTeos Therapeutics by 25.8% during the 3rd quarter. EcoR1 Capital LLC now owns 1,303,157 shares of the company’s stock worth $35,185,000 after acquiring an additional 267,293 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of iTeos Therapeutics by 22.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 71,460 shares of the company’s stock worth $1,929,000 after acquiring an additional 13,330 shares during the period. Tang Capital Management LLC raised its holdings in shares of iTeos Therapeutics by 310.2% during the 3rd quarter. Tang Capital Management LLC now owns 900,000 shares of the company’s stock worth $24,300,000 after acquiring an additional 680,604 shares during the period. Two Sigma Advisers LP raised its holdings in shares of iTeos Therapeutics by 203.9% during the 3rd quarter. Two Sigma Advisers LP now owns 117,600 shares of the company’s stock worth $3,175,000 after acquiring an additional 78,900 shares during the period. Finally, Two Sigma Investments LP raised its holdings in iTeos Therapeutics by 65.9% in the 3rd quarter. Two Sigma Investments LP now owns 167,770 shares of the company’s stock valued at $4,530,000 after buying an additional 66,646 shares during the period. Institutional investors and hedge funds own 98.31% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Read More: What is the strike price in options trading?

Get a free copy of the Zacks research report on iTeos Therapeutics (ITOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.